

**JANELLE F. RUISINGER, PHARM.D.**  
**Curriculum Vitae**

**Personal Information**

Clinical Professor  
Pharmacy Practice  
University of Kansas Medical Center  
3901 Rainbow Blvd; Mail Stop 4047  
Wescoe, 6009K The University of Kansas Hospital  
Kansas City, KS 66160-7231

Email Address: jruisinger@ku.edu  
Office Phone: (913) 588-2608  
Office Fax: (913) 588-2355

**Education**

Doctor of Pharmacy, May 1999  
University of Kansas, Lawrence, KS

Associates of Science, May 1993  
Barton County Community College, Great Bend, KS

**Licensures, Certifications, and Professional Training**

Kansas State Registered Pharmacist #1-13235

Pharmacy Practice Residency with an emphasis on Community Care, The Ohio State University, Columbus, Ohio, July 1999 - June 2000

**Employment History**

Academic

The University of Kansas (KU)  
Clinical Professor, Department of Pharmacy Practice, School of Pharmacy, 2016 - Present

Clinical Assistant Professor, Department of Internal Medicine, School of Medicine, August 2006 - Present

Precept medical students and residents in the University of Kansas Atherosclerosis and LDL-Apheresis Center.

PGY1 Community-Based Pharmacy Residency Director, August 2001 - Present  
Administer the community residency program through program establishment and expansion, recruitment, precepting, and maintaining accreditation.

University of Kansas Medical Center Atherosclerosis and Lipid-Apheresis Center  
Provider, August 2000 - Present

Provide lipid therapy management and cardiovascular risk reduction, through a collaborative practice agreement, in a physician/pharmacist managed lipid specialty clinic.

Clinical Associate Professor, Department of Pharmacy Practice, School of Pharmacy,  
July 2009 - 2016

Develop and implement ambulatory care pharmacy services, participate in practice based research, give didactic lectures, and precept advanced experiential students and community pharmacy practice residents.

Clinical Assistant Professor, Department of Pharmacy Practice, School of Pharmacy,  
August 2000 - July 2009

KU MedWest Antithrombotic Management Service Director, February 2001 - January 2009

Provide point of care service, medication management, counseling, and appointment scheduling in a pharmacist managed anticoagulation clinic.

### **Administrative Assignments**

University of Kansas, Lawrence, KS

Community Pharmacy Residency Director, August 2001 - Present

Support community residency program through establishing a program, recruiting, advising, precepting, site visits and maintaining accreditation.

KU MedWest Antithrombotic Management Service Director, February 2001 - January 2009

Provide point of care service, medication management, counseling, and appointment scheduling in a pharmacist managed anticoagulation clinic.

### **Professional Memberships**

American Pharmacists Association

American Society of Health-System Pharmacists

National Lipid Association (NLA) (2014 - Present)

### **Honors/Awards/Honor Societies**

#### **Group Honors/Awards**

PGY1 Community Pharmacy Residency Program Accreditation, The American Society of Health-System Pharmacists and The American Pharmacists Association (2006 - 2024)

2006-2009, 2009-2012, 2012-2018, 2018-2024

2nd runner up – Best Poster Competition (April 2008)

James M. Backes, Pharm.D., Cheryl A. Gibson, Ph.D., Janelle F. Ruisinger, Pharm.D. and Patrick M. Moriarty, M.D. *Once Weekly Statin Therapy Effective and Well-Tolerated in Patients with a Prior Statin Intolerance*. American College of Clinical Pharmacy (ACCP) Spring Practice and Research Forum, Phoenix, AZ. April 2008

#### **Individual Honors/Awards**

Fellow of the American Pharmacists Association, March 2016 - Present

Appointed to the Commission on Credentialing, American Society of Health-System Pharmacists (August 2013 - December 2019)

University of Kansas School of Pharmacy Ambulatory Care Preceptor of the Year  
Chosen by the graduating class of 2014

Distinguished Achievement Award in Pharmacy Practice, American Pharmacists  
Association Academy of Pharmacy Practice and Management (March 3, 2013)  
Presented at the APhA Annual Meeting, Los Angeles, CA

Preceptor of the Year, University of Kansas School of Pharmacy (2009)  
Chosen by the graduating class of 2009

## **Professional Practice**

### **Clinical Practice**

KUMC Atherosclerosis and Lipid-Apheresis Center  
Set therapeutic goals for patients with elevated cholesterol; prescribe medications  
under a collaborative practice agreement to help patients meet their therapeutic  
goals, order labs, provide patient education. (August 2000 - Present)  
Number of Patients Attended Per Month: 100

## **Research/Scholarly Work**

### **Publications**

#### Book Chapters

Smith, A., & Ruisinger, J. F. (2008). Case 54, Contact Lenses. In *Community Pharmacy Casebook*. American Pharmacists Association. (Peer-reviewed/refereed)

#### Journal Articles

Fanizza FA, Ruisinger JF, Prohaska ES, Melton BL. Integrating a health information exchange into a community pharmacy transitions of care service. *J Am Pharm Assoc*. 2018 Jul - Aug;58(4):442-449. doi: 10.1016/j.japh.2018.02.012. Epub 2018 Apr 4. (Peer-reviewed/refereed)

Klassing, H. M., Ruisinger, J. F., Prohaska, E. S., & Melton, B. M. (2017). Evaluation of Pharmacy-Initiated Interventions on Vaccination Rates in Patients with Asthma or COPD. *J Community Health*. doi:10.1007/s10900-017-0421-9 PMID: 28852915 (Peer-reviewed/refereed)

Funk, R. S., Singh, R. K., Winefield, R. D., Kanel, S. E., Ruisinger, J. F., Moriarty, P. M., & Backes, J. M. (2017). Variability in Potency Among Commercial Preparations of Berberine. *J Diet Suppl*. doi:http://dx.doi.org/10.1080/19390211.2017.1347227 (Peer-reviewed/refereed)

Schulte, N., Ruisinger, J. F., Prohaska, E. S., Steele, K. M., & Melton, B. L. (2017). Comprehensive Medication Review Recipients' Perception of Appointment Offers and Follow-up After Completion. *J Am Pharm Assoc*, 57(3). doi:10.1016/j.japh.2017.01.018 PMID: 28285066 (Peer-reviewed/refereed)

- Backes, J. M., Ruisinger, J. F., Gibson, C. A., & Moriarty, P. M. (2017). Statin-Associated Muscle Symptoms - Managing the Highly Intolerant. *J Clin Lipidol* doi:10.1016/j.jacl.2017.01.006 (Peer-reviewed/refereed)
- Steele, K. M., Ruisinger, J. F., Bates, J., Prohaska, E. S., & Melton, B. L. (2016). Home-based Comprehensive Medication Reviews: Pharmacist Impact on Drug Therapy Problems in Elderly Patients. *Consult Pharm*, 31(10). PMID: 27725070 (Peer-reviewed/refereed)
- Schuessler, T. J., Ruisinger, J. F., Hare, S. E., Prohaska, E. S., & Melton, B. L. (2016). Patient Satisfaction With Pharmacist-Led Chronic Disease State Management Programs. *Journal of pharmacy practice*, 29(5), 484-9. doi:10.1177/0897190014568672 ISSN: 0897-1900 PMID: 25670545 (Peer-reviewed/refereed)
- Backes, J. M., Kostoff, M. D., Gibson, C. A., & Ruisinger, J. F. (2016). Statin-Associated Diabetes Mellitus: Review and Clinical Guide. *Southern medical journal*, 109(3), 167-73. doi:10.14423/SMJ.0000000000000423 ISSN: 0038-4348 PMID: 26954655 (Peer-reviewed/refereed)
- Butler, K. T., Ruisinger, J. F., Bates, J., Prohaska, E. S., & Melton, B. L. (2015). Participant satisfaction with a community-based medication synchronization program. *J Am Pharm Assoc*, 55(5), 534-9. doi:10.1331/JAPhA.2015.14242 ISSN: 1544-3191 PMID: 26359963 (Peer-reviewed/refereed)
- Ruisinger, J. F., Gibson, C. A., Backes, J. M., Smith, B. K., Sullivan, D. K., Moriarty, P. M., & Kris-Etherton, P. (2015). Statins and almonds to lower lipoproteins (the STALL Study). *J Clin Lipidol*, 9, 58-64. PMID: 25670361 (Peer-reviewed/refereed)
- Johnson, C., Ruisinger, J. F., Bates, J., & Barnes, B. J. (2014). Impact of a community-based diabetes self-management program on key metabolic parameters. *Pharmacy practice*, 12(4), 499. ISSN: 1885-642X PMID: 25580174 PMCID: PMC4282769 (Peer-reviewed/refereed)
- Backes, J. M., Ruisinger, J. F., Harris, K. A., Gibson, C. A., Harris, W. S., & Moriarty, P. M. (2014). Evaluating the Effects of Prescription Fish Oil, Supplemental Fish Oil and a Krill Oil Blend on Serum Lipids/Lipoproteins and the Omega-3 Index: A Pilot Study. *Journal of Glycomics & Lipidomics*, 4(4). doi:10.4172/2153-0637.1000121 (Peer-reviewed/refereed)
- Moriarty, P. M., Backes, J., Dutton, J. A., He, J., Ruisinger, J. F., & Schmelzle, K. (2013). Apple pectin for the reduction of niacin-induced flushing. *J Clin Lipidol*, 7(2), 140-6. doi:10.1016/j.jacl.2012.11.005 ISSN: 1933-2874 PMID: 23415433 (Peer-reviewed/refereed)
- Dodson, S. E., Ruisinger, J. F., Howard, P. A., Hare, S. E., & Barnes, B. J. (2012). Community Pharmacy-based medication therapy management services: Financial Impact for Patients. *Pharm Pract*, 10(3), 119-124. (Peer-reviewed/refereed)
- Brna, S. A., Ruisinger, J. F., Howard, P. A., Barnes, B. J., & Hare, S. E. (2012). Study of Nonparticipation in an Employee Diabetes Program. *J Am Pharm Assoc*, 52(5), e105-8. (Peer-reviewed/refereed)

- Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2012). The High Dose Rosuvastatin Once Weekly Study (The HD-ROWS). *J Clin Lipidol*, 6(4), 362-7. (Peer-reviewed/refereed)
- Wiggers, M. E., Ruisinger, J. F., Hare, S. E., Howard, P. A., & Barnes, B. J. (2011). Accuracy and pharmacist perceptions of community-based automated blood pressure machines. *J Am Pharm Assoc*, 51(4), 454-5. (Peer-reviewed/refereed)
- Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2011). Modified-Policosanols Does Not Reduce Plasma Lipoproteins in Hyperlipidemic Patients when Used Alone or in Combination with Statin Therapy. *Lipids*, 46(10), 923-9. (Peer-reviewed/refereed)
- Backes, J. M., Barnes, B. J., Ruisinger, J. F., & Moriarty, P. M. (2011). A Comparison of 25-hydroxyvitamin D Serum Levels Among Those With or Without Statin-associated Myalgias. *Atherosclerosis*, 218(1), 247-9. (Peer-reviewed/refereed)
- Ruisinger, J. F., Koerner, J. M., Backes, J. M., & Moriarty, P. M. (2010). Supratherapeutic Response to Ezetimibe in a Statin Intolerant Patient. *Hospital Pharmacy*, 45, 45-48. (Peer-reviewed/refereed)
- Backes, J. M., Howard, P. A., Ruisinger, J. F., & Moriarty, P. M. (2009). Does Simvastatin Cause More Myotoxicity Compared with Other Statins? *Ann Pharmacother*, 43(12), 2012-20. (Peer-reviewed/refereed)  
(contributed to idea generation, data interpretation, and first/revised drafts of the manuscript)
- Ruisinger, J. F., Backes, J. M., Gibson, C. A., & Moriarty, P. M. (2009). Once Weekly Rosuvastatin (2.5 – 20 mg) in Patients with a Prior Statin Intolerance. *Am J Cardiol*, 103, 393-394. (Peer-reviewed/refereed)  
(contributed to idea generation, research design, data collection/interpretation and first/revised/final drafts of the manuscript)
- Backes, J. M., Carmelo, V. V., Gibson, C. A., & Ruisinger, J. F. (2008). Effectiveness and Tolerability of Every-Other-Day Rosuvastatin in Patients with Prior Statin Intolerance. *Ann Pharmacother*, 42(3), 341-6. (Peer-reviewed/refereed)  
Epub 2008 Feb 19; (contributed to idea generation, research design, data collection/interpretation, and first/revised drafts of the manuscript)
- Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2007). Fibrates: What have we learned in the past 40 years? *Pharmacotherapy*, 27, 412-424. (Peer-reviewed/refereed)  
(contributed to idea generation, data collection/interpretation, and revised drafts of the manuscript)
- Backes, J. M., Moriarty, P. M., Ruisinger, J. F., & Gibson, C. A. (2007). Effects of Once Weekly Rosuvastatin among Patients with a Prior Statin Intolerance. *Am J Cardiol*, 100, 554-555. (Peer-reviewed/refereed)  
(contributed to idea generation, research design, data collection/interpretation, and first/revised drafts of the manuscript)

## Abstracts

- Dodson, S. E., Ruisinger, J. F., Howard, P. A., Hare, S. E., & Barnes, B. J. (2011). Community Pharmacy-Based Medication Therapy Management Services: Financial Impact for Patients. *J Am Pharm Assoc*, 51, 256. (Peer-reviewed/refereed)
- Wiggers, M., Ruisinger, J., Hare, S., Howard, P., & Barnes, B. (2009). Accuracy and pharmacist perceptions of community-based automated blood pressure machines. *J Am Pharm Assoc*, 49, 238. (Peer-reviewed/refereed)
- Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2008). Once Weekly Statin Therapy Effective and Well-tolerated in Patients with a Prior Statin Intolerance. *Pharmacotherapy*, 28, 39e. (Peer-reviewed/refereed)
- Backes, J. M., Ruisinger, J. F., Gibson, C. A., & Moriarty, P. M. (2008). Effects of Policosanol when Used in a Lipid-specialty Clinic. *Pharmacotherapy*, 28, 46e. (Peer-reviewed/refereed)
- Emming, V., Wilhelm, M., Ruisinger, J., & Howard, P. (2008). Acceptance and Impact of Pharmacist Interventions in an Outpatient Blood Pressure Management Clinic. *J Am Pharm Assoc*, 48(2), 252. (Peer-reviewed/refereed)
- Koerner, J., Wilhelm, M., Ruisinger, J., & Grauer, D. (2007). Effectiveness of a collaborative pharmacist-dietitian taught diabetes education program. *J Am Pharm Assoc*, 47, 238. (Peer-reviewed/refereed)
- Moriarty, P., Backes, J., Ruisinger, J., & Gibson, C. (2007). Once Weekly Dose of Rosuvastatin for Patients with Prior Statin Intolerance. *J Clin Lipidol*, 1(5), 326. (Peer-reviewed/refereed)
- Backes, J. M., Gibson, C. A., Hanson, N. E., Gons, A. D., Ruisinger, J. F., & Moriarty, P. M. (2006). Statin therapy effective and better tolerated when administered every other day among patients with previous adverse effects. *Pharmacotherapy*, 26, e52. (Peer-reviewed/refereed)
- Smith, A., Grauer, D., Ruisinger, J., & Halliwell, M. (2006). Evaluation of pharmacists' attitudes and perceptions in relation to medication therapy management services. *J Am Pharm Assoc*, 46, 252. (Peer-reviewed/refereed)
- Backes, J., Calish, J., Gibson, C., Ruisinger, J., Rush, E., & Moriarty, P. (2005). Fenofibrate Impacts a Greater Number of Cardiovascular Risk Factors Compared to Atorvastatin in Treating Mixed Dyslipidemia Among Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus. *Pharmacotherapy*, 25, 454-455. (Peer-reviewed/refereed)
- Stack, T., Grauer, D., Ruisinger, J., Kerner, S., & Wilhelm, M. (2005). Development of an instrument to measure medication health literacy. *J Am Pharm Assoc*, 46, 233. (Peer-reviewed/refereed)

## Journals, Special Issues

- Bleidt, B., & Ruisinger, J. (2006). Triglycerides, HDL cholesterol and other secondary targets of lipid-lowering therapy. *APhA Special Report, Supplement to Pharmacy Today*. (Peer-reviewed/refereed)

### Letter to Editor

- Ruisinger JF, Moriarty PM, Backes JM. Coenzyme Q10 for statin-associated myalgia. *Am J Health Syst Pharm*. 2018 Jan 15;75(2):14-15. doi: 10.2146/ajhp170551. (Peer-reviewed/refereed)
- Backes, J. M., Ruisinger, J. F., Barnes, B. J., & Moriarty, P. M. (2015). Statin Intolerance and Vitamin D Supplementation: Sunny, but a Few Clouds Remain.... In *N Am J Med Sci*. 2015 Jul;7(7):337-8. doi: 10.4103/1947-2714.161255. (Peer-reviewed/refereed)

### Posters

- Litwin L, Ruisinger J, Melton B, Prohaska E, Steele K. *Perception of Interpretation Services for Patients with English as a Second Language During Pharmacist-Led Chronic Disease State Management Programs*  
Presented at the American Pharmacists Association Annual Meeting, Nashville, TN. Proceedings: *J Am Pharm Assoc* 2018 May-June;58(3):e126
- Luchen G, Prohaska E, Ruisinger J, Melton B. *Impact of Community Pharmacist Intervention on Concurrent Benzodiazepine and Opioid Prescribing Patterns*  
Presented at the American Pharmacists Association Annual Meeting, Nashville, TN. Proceedings: *J Am Pharm Assoc* 2018 May-June;58(3):e166
- Fanizza F, Prohaska E, Ruisinger J, Melton B. *Effect of a Community Pharmacy Self-Referral Transitions of Care Service on 30-Day Hospital Readmission Rates*.  
Presented at the American Pharmacists Association Annual Meeting, San Francisco, CA. Proceedings: *J Am Pharm Assoc* 2017 May-June;57(3):e134
- Bennett S, Prohaska E, Steele K, Ruisinger J, Melton B. *Assessing Pet Owner and Veterinarian Perceptions of Need for Veterinary Compounding Services in a Community Pharmacy Setting*.  
Presented at the American Pharmacists Association Annual Meeting, San Francisco, CA. Proceedings: *J Am Pharm Assoc* 2017 May-June;57(3):e80
- Graham E, Prohaska E, Ruisinger J, Melton B. *The Effect of Multi-Dose Packaging on Select Medical Part D Star Rating Measurements*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, Baltimore, MD. Proceedings: *J Am Pharm Assoc* 2016 May-June;56(3):e6
- Schulte N, Ruisinger J, Prohaska E, Melton B. *Assessment of Factors Influencing Patient Acceptance and Perception of Comprehensive Medication Reviews*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, Baltimore, MD. Proceedings: *J Am Pharm Assoc* 2016 May-June;56(3):e67
- Palmer, H., Ruisinger, J., Prohaska, E., & Melton, B. M. (2015). *Evaluation of Pharmacy-Initiated Interventions on Vaccination Rates in Patients with Asthma or COPD*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, San Diego, CA. Proceedings: *J Am Pharm Assoc* 2015 Mar-Apr;55(2):e159



- Steele, K., Ruisinger, J., Prohaska, E., & Melton, B. M. (2015). *The Effect of Home-based Comprehensive Medication Reviews on Triple-Weighted CMS Star Rating Measurement*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, San Diego, CA. Proceedings: J Am Pharm Assoc 2015 Mar-Apr;55(2):e175
- Butler, K. T., Ruisinger, J., Bates, J., & Melton, B. M. (2014). *Patient Satisfaction with a Community-Based Medication Synchronization Program*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, Orlando, FL. Proceedings: J Am Pharm Assoc 2014 Mar-Apr;54(2):e159
- Schuessler, T. J., Ruisinger, J., Hare, S. E., & Melton, B. L. (2014). *Patient Satisfaction with Pharmacist-led Chronic Disease State Management Programs*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, Orlando, FL. Proceedings: J Am Pharm Assoc 2014 Mar-Apr;54(2):e159-e160
- Ruisinger, J., Backes, J. M., Harris, K., Gibson, C., Harris, W., & Moriarty, P. M. (2013). *Evaluating the Effects of Krill Oil, Supplemental Fish Oil and Prescription Fish Oil on Lipoproteins and Gastrointestinal Symptoms – A Randomized Controlled Trial*. (Peer-reviewed/refereed)  
Presented at the American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM. Proceedings: Pharmacotherapy 2013;33(10)e210
- Backes, J. M., Ruisinger, J., Gibson, C., Varvel, S., & Moriarty, P. M. (2013). *The High-Dose Rosuvastatin Once Weekly Study (HD-ROWS) – The Effects on Advanced Lipid, Glycemic, and Inflammatory Panels*. (Peer-reviewed/refereed)  
Presented at the American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM. Proceedings: Pharmacotherapy 2013;33(10)e188
- Byrd, A., Ruisinger, J., Barnes, B. J., & Backes, J. M. (2013). *The Impact of a Weekly Weigh-In versus Nutrition Education on Body Weight Indices within an Employee Wellness Program*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, Los Angeles, CA. Proceedings: J Am Pharm Assoc 2013 March-Apr;53(2):e73
- Johnson, C., Ruisinger, J., Barnes, B. J., & Vink, J. (2013). *Impact of a Community-Based Diabetes Self-Management Program on Key Metabolic Parameters*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, Los Angeles, CA. Proceedings: J Am Pharm Assoc 2013 Mar-Apr;53(2):e32
- Schuessler, B., Ruisinger, J., Grauer, D. W., Moriarty, P. M., & Backes, J. M. (2012). *Comparison of vitamin D dosing regimens in non-obese and obese patients with low vitamin d levels*. (Peer-reviewed/refereed)  
Presented at the American College of Clinical Pharmacy Annual Meeting, Hollywood, FL.



- Moriarty, P. M., Backes, J. M., Ruisinger, J. F., He, J., Schmelzle, K., & Dutton, J. A. (2012). *Apple-pectin and its ability to reduce niacin-induced flushing*. Moderated poster at the 80th European Atherosclerosis Society Congress, Milan, Italy.
- Applegate, A., Ruisinger, J., Howard, P. A., & Barnes, B. J. (2012). *Perceived Role of Pharmacists Providing Nutritional Counseling: Difference Between Patients and Pharmacists and Impact of Geographic Area*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, New Orleans, LA. Proceedings: J Am Pharm Assoc 2012 March-Apr; 52(2):250
- Moriarty, P. M., Gibson, C. A., Backes, J. M., Eldringhoff, D., Powell, S., & Ruisinger, J. F. (2011). *The effect of aggressive cardiovascular treatment on the progression of carotid intima-media thickness: Experience of an atherosclerosis prevention center*. (Peer-reviewed/refereed)  
Presented at the 79th European Atherosclerosis Society Congress, Gothenberg, Sweden.
- Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2011). *High-dose rosuvastatin once weekly study (HD-ROWS)*. (Peer-reviewed/refereed)  
Presented at the 79th European Atherosclerosis Society Congress, Gothenberg, Sweden.
- Dodson, S. E., Ruisinger, J. F., Howard, P. A., Hare, S. E., & Barnes, B. J. (2010). *Community pharmacy-based medication therapy management services: financial impact for patients*.  
Poster presented at American Society of Health-System Pharmacy Midyear Clinical Meeting Resident Poster Session, Anaheim, CA.
- Eldringhoff, D. M., Backes, J. M., Ruisinger, J. F., Dutton, J. S., Barnes, B. J., Belmont, J. M., & Moriarty, P. M. (2010). *Aggressive treatment of cardiovascular risk factors results in the reduction of atherosclerosis growth as measured by carotid intima media thickness: experience from an atherosclerosis prevention clinic*. (Peer-reviewed/refereed)  
Presented at the International Academy of Cardiology, 15th World Congress on Heart Disease, Vancouver, BC, Canada.
- Brna, S. A., Ruisinger, J. F., Howard, P. A., Barnes, B. J., & Hare, S. E. (2009). *Study of Non-participation in an Employee Diabetes Program*.  
American Society of Health System Pharmacists Midyear Clinical Meeting Resident Poster Session, Las Vegas, NV.
- Wiggers, M. E., Ruisinger, J. F., Hare, S. E., Howard, P. A., & Barnes, B. J. (2009). *Accuracy and Pharmacist Perceptions of Community-based Automated Blood Pressure Machines*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting Resident Poster Session, San Antonio, TX.

- Moriarty, P. M., Barnes, B. J., Ruisinger, J. F., & Backes, J. M. (2009). *Assessment of Accelerated Atherosclerosis in Asymptomatic Firemen: The 4 "A"larm Study*. (Peer-reviewed/refereed)  
Presented at the Joint Conference - 49th Cardiovascular Disease Epidemiology and Prevention Annual Conference, and Nutrition, Physical Activity and Metabolism Conference, Palm Harbor, FL.
- Wiggers, M. E., Ruisinger, J. F., Hare, S. E., Howard, P. A., & Barnes, B. J. (2008). *Accuracy and Pharmacist Perceptions of Community-based Automated Blood Pressure Machines*.  
American Society of Health-System Pharmacy Midyear Clinical Meeting Resident Poster Session, Orlando, FL.
- Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2008). *Once Weekly Statin Therapy Effective and Well-Tolerated in Patients with a Prior Statin Intolerance*. (Peer-reviewed/refereed)  
Presented at the American College of Clinical Pharmacy Spring Practice and Research Forum, Phoenix, AZ.
- Backes, J. M., Ruisinger, J. F., Gibson, C. A., & Moriarty, P. M. (2008). *Effects of Policosanol when used in a Lipid-Specialty Clinic*. (Peer-reviewed/refereed)  
Presented at the American College of Clinical Pharmacy Spring Practice and Research Forum, Phoenix, AZ.
- Emming, V. J., Wilhelm, M. J., Ruisinger, J. F., & Howard, P. A. (2008). *Acceptance and Impact of Pharmacist Interventions in an Outpatient Hypertension Management Clinic*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, San Diego, CA.
- Emming, V. J., Wilhelm, M. J., Ruisinger, J. F., & Howard, P. A. (2007). *Acceptance and Impact of Pharmacist Interventions in an Outpatient Hypertension Management Clinic*.  
American Society of Health-System Pharmacists Midyear Clinical Meeting Resident Poster Session, Las Vegas, NV.
- Koerner, J., Wilhelm, M., Ruisinger, J. F., & Grauer, D. (2007). *Effectiveness of a Collaborative Pharmacist-Dietitian Taught Diabetes Education Program*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, Atlanta, GA.
- Koerner, J., Wilhelm, M., Ruisinger, J., & Grauer, D. (2006). *Effectiveness of a Collaborative Pharmacist-Dietitian Taught Diabetes Education Program*.  
American Society of Health-System Pharmacists Midyear Clinical Meeting Resident Poster Session, Anaheim, CA.
- Smith, A., Grauer, D., Ruisinger, J. F., & Halliwell, M. (2006). *Evaluation of Pharmacists' Attitudes and Perceptions in Relation to Medication Therapy Management Services and Overall Patient Care Initiatives within the Supermarket Pharmacy Model*. (Peer-reviewed/refereed)  
Presented at the American Pharmacists Association Annual Meeting, San Francisco, CA.

Smith, A., Grauer, D., Ruisinger, J., & Halliwell, M. (2005). *Evaluation of Pharmacists' Attitudes and Perceptions in Relation to Medication Therapy Management Services and Overall Patient Care Initiatives within the Supermarket Pharmacy Model*. American Society of Health – System Pharmacists Midyear Clinical Meeting Resident Poster Session, Las Vegas, NV.

Backes, J., Calish, J., Gibson, C., Ruisinger, J. F., Rush, E., & Moriarty, P. (2005). *Fenofibrate Impacts a Greater Number of Cardiovascular Risk Factors Compared to Atorvastatin in Treating Mixed Dyslipidemia Among Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus*. (Peer-reviewed/refereed) Presented at the American College of Clinical Pharmacy Spring Practice and Research Forum Poster Session, Myrtle Beach, SC.

Stack, T., Grauer, D., Ruisinger, J., & Wilhelm, M. (2004). *Development of An Instrument to Measure Medication Literacy*. Poster presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting, Resident Poster Session, Orlando, FL

Schuster, M., Grauer, D., Ruisinger, J., & Denton, J. (2002). *Prescription Savings Program for Older Adults*. Poster presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting, Resident Poster Session, Atlanta, GA

## **Invited Presentations/Lectures**

### **International**

Ruisinger, J. F. (2004, October). *Anticoagulation Journal Club – Review of Practice Guidelines*. Kyoritsu University of Pharmacy, Tokyo, Japan.

Ruisinger, J. F. (2004, October). *Anticoagulation in the United States*. Keio University Medical Center Department of Pharmacy, Tokyo, Japan.

Ruisinger, J. F. (2004, October). *Case studies in Monitoring Patients on Lipid-Lowering Therapy*. Kyoritsu University of Pharmacy, Tokyo, Japan.

Ruisinger, J. F. (2004, October). *Case studies in Monitoring Patients on Warfarin*. Kyoritsu University of Pharmacy, Tokyo, Japan.

Ruisinger, J. F. (2004, October). *Lipid Journal Club – Review of Practice Guidelines*. Kyoritsu University of Pharmacy, Tokyo, Japan.

Ruisinger, J. F. (2004, October). *The Role of a Pharmacist in an Anticoagulation Clinic*. Kyoritsu University of Pharmacy, Tokyo, Japan.

### **National**

(2015, March). *Creating Clarity for Very High Triglycerides (VHTG) Care*. American Pharmacists Association Annual Meeting, San Diego, CA.

Koerner, J., Wilhelm, M., Ruisinger, J., & Grauer, D. (2007, June). *Effectiveness of a collaborative pharmacist-dietitian taught diabetes education program*. Platform Presentation at the 2007 APhA Self Care Institute, Philadelphia, PA. (contributed to idea generation, research design, data interpretation, and revised drafts of the presentation)

## State

Ruisinger, J. F. (2000, February). *Pharmacists' Role in Hepatitis C Treatment*. Presented at the 2nd Annual Central Ohio Hepatitis C Awareness Conference to patients with hepatitis and their families, social workers, and nurses.

## Local

Ruisinger, J. F. (2006, February). *Anticoagulation with Warfarin*. Presented to physicians and nurses at KU MedWest, Shawnee, KS.

## Presentations/Lectures

### International

Moriarty, P., Backes, J., Ruisinger, J., & Gibson, C. (2007, October 4). *Once Weekly Dose of Rosuvastatin for Patients with Prior Statin Intolerance*. Platform Presentation at the XVI International Symposium on Drugs Affecting Lipid Metabolism (DALM), New York, NY.

### National

Backes, J. M., Ruisinger, J. F., Winefield, R., Singh, R. K., Moriarty, P. M., & Funk, R. S. (2016, October). *Pronounced Variability of Berberine Content Among 15 Commercial Dietary Preparations*. The American College of Clinical Pharmacy Annual Meeting, Hollywood, FL. (Peer-reviewed/refereed)

Ruisinger, J. F., Backes, J. M., & Moriarty, P. M. (2016, August). *Statins Wrongly Accused of Causing Myalgia – Guilty By Association*. National Lipid Association Scientific Sessions, New Orleans, LA. (Peer-reviewed/refereed)

Backes, J. M., Melton, B. L., Ruisinger, J. F., Burkhardt, C. D., & Moriarty, P. M. (2016, May). *A Comparison of Patients' Prescribed, Self-Reported, and Actual Intake of Supplemental EPA/DHA*. National Lipid Association Scientific Sessions, New Orleans, LA. (Peer-reviewed/refereed)

Graham, E. E., Prohaska, E. S., Ruisinger, J. F., & Melton, B. L. (2016, March). *The Effect of Multi-Compartment Adherence Packaging on Medicare Part D Adherence Related Star Rating Measurements*. American Pharmacists Association Annual Meeting, Baltimore, MD: J Am Pharm Assoc. 2016;56(3):e6. (Peer-reviewed/refereed)

Schulte, N., Ruisinger, J., Prohaska, E., Melton, B., & Steele, K. (2016, March). *Assessment of Factors Influencing Patient Acceptance and Perception of Comprehensive Medication Reviews*. American Pharmacists Association Annual Meeting, Baltimore, MD: J Am Pharm Assoc. 2016;56(3):e6. (Peer-reviewed/refereed)

- Palmer, H., Ruisinger, J., Prohaska, E., & Melton, B. (2015, March). *Evaluation of Pharmacy-Initiated Interventions on Vaccination Rates in Patients with Asthma or COPD*. American Pharmacists Association Annual Meeting, San Diego, CA: J Am Pharm Assoc. 2015;55(2):e159. (Peer-reviewed/refereed)
- Steele, K., Ruisinger, J., Prohaska, E., & Melton, B. (2015, March). *The Effect of Home-based Comprehensive Medication Reviews on Triple-Weighted CMS Star Rating Measurement*. American Pharmacists Association Annual Meeting, San Diego, CA: J Am Pharm Assoc. 2015;55(2):e175. (Peer-reviewed/refereed)
- Butler, K., Ruisinger, J., Bates, J., & Melton, B. (2014, March). *Patient Satisfaction with a Community-Based Medication Synchronization Program*. American Pharmacist Association Annual Meeting, Orlando, FL: J Am Pharm Assoc. 2014;54(2):e159. (Peer-reviewed/refereed)
- Schuessler, T., Ruisinger, J., Hare, S., & Melton, B. (2014, March). *Patient Satisfaction with Pharmacist-led Chronic Disease State Management Programs*. American Pharmacists Association Annual Meeting, Or: J Am Pharm Assoc. 2014;54(2):e159-e160. (Peer-reviewed/refereed)
- Backes, J. M., Ruisinger, J. F., Gibson, C., Varvel, S., & Moriarty, P. M. (2013, October). *The High-Dose Rosuvastatin Once Weekly Study (HD-ROWS) – The Effects on Advanced Lipid, Glycemic, and Inflammatory Panels*. American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM: Pharmacotherapy. 2013;33(10)e188. (Peer-reviewed/refereed)
- Ruisinger, J. F., Backes, J. M., Harris, K., Gibson, C., Harris, W., & Moriarty, P. M. (2013, October). *Evaluating the Effects of Krill Oil, Supplemental Fish Oil and Prescription Fish Oil on Lipoproteins and Gastrointestinal Symptoms – A Randomized Controlled Trial*. The American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM: Pharmacotherapy. 2013;33(10)e210. (Peer-reviewed/refereed)
- Backes, J., Gibson, C., Hanson, N. E., Gons, A. D., Ruisinger, J., & Moriarty, P. (2006, October). *Statin therapy effective and better tolerated when administered every other day among patients with previous adverse effects*. 2006 Annual Meeting of the American College of Clinical Pharmacy Annual Meeting Platform Presentation during the Scientific Paper Platform session, St. Louis, MO.

## Continuing Education Presentations

### National

- Ruisinger J. (2015, June 25). *Positively Impacting Performance Measures One Patient at a Time*. McKesson 2015 ideaShare Conference, San Diego, CA. (Peer-reviewed/refereed)
- Ruisinger, J. (2014, July 20). *Statins and Statin Adherence: The Good, the Bad, ...Well Really It Is Mostly Ugly*. McKesson 2014 ideaShare Conference, Orlando, FL. (Peer-reviewed/refereed)

Ruisinger, J. (2012, March 11). *Good to Great*. PGY1 Community Pharmacy Residency Programs Continuing Education Session invited CE program presented at the APhA Annual Meeting and Exposition, New Orleans, LA.

Ruisinger, J. (2011, March 27). *Good to Great*. PGY1 Community Pharmacy Residency Programs Continuing Education Session invited CE program presented at the APhA Annual Meeting and Exposition, Seattle, WA.

Ruisinger, J. (2006, March 18). *Triglycerides, HDL Cholesterol, and Other Secondary Targets of Lipid-Lowering Therapy*. Invited CE program presented at the APhA Annual Meeting and Exposition, San Francisco, CA.

Ruisinger, J. (2005, July 13). *Pharmacy Based Lipid Management*. ACPE approved certification program sponsored by American Pharmacists Association (APhA), Las Vegas, NV.

Tavalali, S., PharmD, & Ruisinger, J. (2005, April). *The Life of a Resident: A Glimpse at the Next Twelve Months*. Clinical pearl presented at the American Pharmacists Association Annual Meeting, Orlando, FL.  
(contributed to idea generation, data interpretation, and revised drafts of the presentation)

Ruisinger, J. (2004, April). *Fish Oil*. Clinical pearl presented at the American Pharmacists Association Annual Meeting, Seattle, WA.

## State

Ruisinger, J. (2004, July). *New Drugs for 2004*. Presented at 15th Annual Kansas School Nurse Conference, Wichita, KS.

Ruisinger, J. (2003, October). *Pharmacology Update*. Presented at Kansas State Nurses Association Annual Fall Convention, Kansas City, MO.

Ruisinger, J. (2001, October). *New Drugs of the New Millennium*. Education seminar presented at the Kansas State Nurses Association Annual Fall Convention, Kansas City, MO.

## Local

Ruisinger, J., Moriarty, P., & Backes, J. (2011, August 10). *Interdisciplinary Research in a Clinical Setting: From Fruits to Nuts, alternative methods in treating atherosclerosis and dyslipidemia*. Internal Medicine Grand Rounds (CE). University of Kansas Medical Center, Kansas City, KS.  
(Co-presented with Patrick Moriarty, MD and James Backes, Pharm.D)

Ruisinger, J. (2011, February). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.

Ruisinger, J. (2009, August). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.



- Ruisinger, J. (2008, August). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2007, September). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2007, April). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2007, Spring). *Lipid Management – A Curricular Based Course for Pharmacists*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2006, October). *Keeping Current: Immunization Update*. ACPE approved CE program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2006, May). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2006, Spring). *Lipid Management – A Curricular Based Course for Pharmacists*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2005, May). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2005, Spring). *Lipid Management – A Curricular Based Course for Pharmacists*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2004, August). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2004, March). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2003, September). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.
- Ruisinger, J. (2003, March). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.



Ruisinger, J. (2002, September). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.

Ruisinger, J. (2002, March). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.

Ruisinger, J. (2001, November). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.

Ruisinger, J. (2001, March). *Pharmacist Based Immunization Delivery*. ACPE approved certification program sponsored by The University of Kansas School of Pharmacy, Lawrence, KS.

## **Research Funding/Fellowships**

### **University of Kansas**

#### **Externally-Funded Grant/Contract**

##### Funded

Dollar K, Prohaska E, Ruisinger J, Melton B. *Public Awareness of Mental Health First Aid and Perception of Community Pharmacists as Mental Health First Aid Providers*. American Pharmacists Association Foundation \$1,000 (January 2019 - December 2019).

Litwin L, Ruisinger J, Melton B, Prohaska E, Steele K. *Perception of Interpretation Services for Patients with English as a Second Language during Pharmacist-Led Chronic Disease State Management Programs*. American Pharmacists Association Foundation \$1,000 (January 2018 - December 2018).

Luchen G, Prohaska E, Ruisinger J, Melton B. *Impact of Community Pharmacist Intervention on Concurrent Benzodiazepine and Opioid Prescribing Patterns*. American Pharmacists Association Foundation \$1,000 (January 2018 - December 2018).

Moriarty, P. M., Backes, J. M., Ruisinger, J. F. (Co-Investigator), & Chonko, A. *A Multicenter, Controlled, Open-Label Extension Study to Assess the Long-term Safety and Efficacy of AMG145 (OSLER-2)*. Amgen \$39,798 (2015 - Present).

Moriarty, P. M. (Principal), Backes, J. M. (Co-Investigator), & Ruisinger, J. F. (Co-Investigator). *A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects (GAUSS-3)*. Amgen \$175,188 (2014 - Present).

Moriarty, P. M. (Principal), Backes, J. M. (Co-Investigator), Ruisinger, J. F. (Co-Investigator), & Chonko, A. (Co-Investigator). *Open-Label Extension Study of EFC12492, R727-CL-112, EFC12732, & LT11717 Studies to Assess the Long-Term Safety and Efficacy of (Study Drug) In Patients with Heterozygous Familial Hypercholesterolemia*. Sanofi \$105,219 (2014 - Present).

Moriarty, P. M., Backes, J. M., Ruisinger, J. F. (Co-Principal), Chonko, A., & Vacek, J. A. *Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When (Study Drug) is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease*. Amgen \$688,407 (2013 - Present).  
Competitive. Funded for 40 patients. Enrollment ongoing

Moriarty, P. M. (Principal), Backes, J. M. (Co-Investigator), & Ruisinger, J. F. (Co-Investigator). *A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins*. Regeneron \$501,636 (2013 - Present).

Moriarty, P. M., Backes, J. M., Ruisinger, J. F. (Co-Investigator), & Chonko, A. *Long-term safety and tolerability of (Study Drug) in high cardiovascular risk patients with hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, double-blind, placebo-controlled study*. Sanofi \$56,648 (2013 - Present).  
Competitive. 4 patients enrolled

Moriarty, P. M., Backes, J. M., Ruisinger, J. F. (Co-Investigator), & Chonko, A. *Study to Evaluate the Effect of SAR236553 REGN727 on the Occurrence of Cardiovascular Patients Who Have Recently Experienced and Acute Coronary Syndrome (ODYSSEY-OUTCOMES)*. Sanofi \$257,725 (2013 - Present).

Moriarty, P. M., MD, Backes, J. M., PharmD, Ruisinger, J. F., PharmD (Co-Investigator), & Chonko, A., MD. *A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of (Study Drug) administered by subcutaneous injection in patients with Heterozygous Familial Hypercholesterolemia*. Regeneron Pharmaceuticals, Inc \$22,758 (September 2012 - Present).  
Competitive contract is for max \$22,758, for 1 patient

Moriarty, P. M., Backes, J. M., Ruisinger, J. F. (Co-Investigator), & Chonko, A. *A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different Regimens of (study Drug) in Patients with Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol*. Genzyme Corporation (2012 - Present).  
\$17,496/patient. 3 patients enrolled, 5 patients expected. Competitive grant

Moriarty, P. M., Backes, J. M., Ruisinger, J. F. (Co-Investigator), Chonko, A., & Vacek, J. *A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous Canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP (CANTOS).* Novartis \$136,583 (2012 - Present).

Moriarty, P. M., Backes, J. M., Ruisinger, J. F. (Co-Investigator), & Chonko, A. *A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of (study drug) in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy.* Sanofi US, Inc (2012 - Present).  
\$12,450/pt; contract for up to 18 patients, with at least 6 - 7 enrolled, competitive

Moriarty, P. M., Backes, J. M., Ruisinger, J. F. (Co-Investigator), Chonko, A., & Vacek, J. *A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of (Study Drug) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.* Sanofi US, Inc (2013 - 2018).  
Total Direct Award - 20 (up to 30), \$19,825/patient

Fanizza, F. (Principal), Prohaska, E. S. (Co-Investigator), Ruisinger, J. F. (Co-Investigator), & Melton, B. L. (Co-Investigator). *Drug Therapy Problems Identified Through a Self-Referral Transitions of Care Service Offered in a Community Pharmacy.* American Pharmacists Association Foundation \$1,000 (January 2017 - December 2017).

Schulte, N. (Principal), Ruisinger, J. F. (Co-Investigator), Prohaska, E. S. (Co-Investigator), Melton, B. L. (Co-Investigator), & Steele, K. (Co-Investigator). *Assessment of Factors Influencing Patient Acceptance and Perception of Comprehensive Medication Reviews.*, American Pharmacists Association Foundation \$1,000 (January 2016 - December 2016).

Graham, E. E. (Principal), Prohaska, E. S. (Co-Investigator), Ruisinger, J. F. (Co-Investigator), & Melton, B. L. (Co-Investigator). *The Effect of Multi-Compartment Adherence Packaging on Medicare Part D Adherence Related Star Rating Measurements.* American Pharmacists Association Foundation \$1,000 (January 2016 - December 2016).

Moriarty, P. M. (Principal), Backes, J. M. (Co-Investigator), & Ruisinger, J. F. (Co-Investigator). *A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipid apheresis therapy (ESCAPE).* Regeneron \$157,639 (2015 - 2016).

Palmer, H., PharmD (Principal), Ruisinger, J.F. (Co-Investigator), Prohaska, E., PharmD (Co-Investigator), & Melton, B. M., PhD (Co-Investigator). *Evaluation of Pharmacy-Initiated Interventions on Vaccination Rates in Patients with Asthma or COPD.* American Pharmacists Association Foundation \$1,000, Submitted October 2014 (January 2015 - December 2015).

- Steele, K., PharmD (Principal), Ruisinger, J.F. (Co-Investigator), Bates, J., PharmD (Co-Investigator), & Melton, B. L., PhD (Co-Investigator). *The Effect of Home-based Comprehensive Medication Reviews on Triple-Weighted CMS Star Rating Measurements*. American Pharmacists Association Foundation \$1,000, Submitted October 2014 (January 2015 - December 2015).
- Ruisinger, JF. *NACDS Foundation Community Pharmacy Residency Expansion Project (Community PREP)*. National Association of Chain Drug Stores (NACDS) Foundation \$50,000, Submitted July 2011 (July 1, 2012 - June 30, 2015).
- Butler, K. (Principal), & Ruisinger, J. F. (Co-Investigator). *Implementation and Assessment of a Community-Based Medication Synchronization Program*. The American Pharmacists Association Foundation \$1,000, Submitted December 2013 (January 2014 - December 2014).
- Moriarty, P. M., Backes, J. M., Ruisinger, J. F. (Co-Investigator), & Chonko, A. A *Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of (Study Drug) in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins*. Regeneron Pharmaceuticals, Inc (January 2013 - 2014).  
Competitive. Funding: (\$10,188/patient. Contracted for 8 patients) 9 patients
- Moriarty, P. M., Backes, J. M., Dutton, J. A., & Ruisinger, J. F. (Co-Investigator). *A Study comparing the effects of Pitavastatin, Atorvastatin, and Rosuvastatin on plasma levels of CoQ10 (SPARQ)*. Kowa and Lilly Pharmaceuticals \$776,000 (January 2012 - January 2014).
- Moriarty, P. M., Backes, J. M., & Ruisinger, J. F. (Co-Investigator). *A Randomized, Double Blind, Placebo-Controlled, 12-week Study of the Safety and Efficacy of REGN727 (Study Drug) in Patients with Heterozygous Familial Hypercholesterolemia (Phase 2 Clinical Trial)*. Regeneron Pharmaceuticals, Inc (January 2011 - July 2012).
- Moriarty, P. M., Backes, J. M., & Ruisinger, J. F. (Co-Investigator). *A Multi-Center, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) (Study Drug) in Patients with Hyperlipidemia (Phase 2 Clinical Trial)*. Beijing Peking University WBL Biotech Co. LTD (January 2011 - December 2011).  
\$4,595.00 per completed patient; 19 enrolled
- Dodson, S. E. (Principal), & Ruisinger, J. F. (Co-Investigator). *Community pharmacy-based medication therapy management services: financial impact for patients*. American Pharmacists Association Foundation \$1,000, Submitted December 2010 (January 2011 - December 2011).
- Moriarty, P. M., Backes, J. M., & Ruisinger, J. F. *Alternative Options to Minimize Niacin-Induced Flushing – A Pilot Study*. Abbott Laboratories \$165,471 (September 2009 - December 2011).
- Wiggers, M. E., Ruisinger, J. F., Hare, S. E., Howard, P. A., & Barnes, B. J. *Accuracy and pharmacist perceptions of community-based automated blood pressure machines*. American Pharmacists Association (APhA) Foundation Incentive Grant \$1,000 (January 2009 - December 2009).

Moriarty, P. M., Backes, J. M., & Ruisinger, J. F. *An open-label, dose-escalating efficacy and safety study of implitapide at daily doses of 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, and 40mg in patients with hypertriglyceridemia (HTG) on maximal, concurrent triglyceride-lowering therapy.* Pharmaco Investments, Inc \$16,780 (March 2005 - March 2007).

Koerner, J., Wilhelm, M., Ruisinger, J., & Grauer, D. *Effectiveness of a collaborative pharmacist-dietitian taught diabetes education program.* American Pharmacists Association Foundation Incentive Grant \$1,000 (January 2006 - January 2007).

Moriarty, P. M., Ruisinger, J. F., & Backes, J. M. *A double-blind, randomized, dose-escalating efficacy and safety study of implitapide at daily doses of 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, and 40 mg compared with placebo in patients with heterozygous familial hypercholesterolemia (HeFH) on maximal, tolerable, concurrent lipid-lowering therapy.* Pharmaco Investments, Inc \$21,855 (December 2004 - December 2006).

Stack, T., Grauer, D., Ruisinger, J., & Wilhelm, M. *Development of an Instrument to Measure Medication Literacy.* American Pharmacists Association Foundation Incentive Grant \$1,000 (January 2005 - January 2006).

Moriarty, P. M., Ruisinger, J. F., & Backes, J. M. *Extended Release Nicacin and Its Effect on Inflammatory Markers, Pro-insulin and Blood Viscosity.* Kos Pharmaceuticals \$11,087 (December 2003 - December 2004).

#### Not Funded

Moriarty, P. M., Backes, J. M., & Ruisinger, J. F. *Effect of Rosiglitazone on Blood Viscosity and Inflammatory Markers in Patients with Metabolic Syndrome.* GlaxoSmithKline \$230,480, Submitted March 2006.

Moriarty, P. M., Ruisinger, J. F., & Backes, J. M. *Effects of Pioglitazone on Vascular Function, as Measured by Blood Pressure Changes, and its Association to Changes in Hemorrheology among Patients with Metabolic Syndrome.* Takeda Pharmaceutical Company \$246,105, Submitted July 2006.

Backes, J. M., Moriarty, P. M., Ruisinger, J. F., & Gibson, C. A. *Fenofibrate and Its Effects on Inflammatory Markers and Blood Viscosity.* Abbott Laboratories \$79,825, Submitted April 2002.

#### **General Research Fund**

##### Funded

Backes, J. M. (Principal), & Ruisinger, J. F. (Co-Investigator). *Evaluating the Tolerability and Effects of Krill Oil on Major Lipoproteins and the Omega-3 Index: A Pilot Study.* University of Kansas General Research Fund and lab support provided by HDLabs \$33,280 (June 2011 - May 2012).

(Principal), Backes, J. M., PharmD (Co-Investigator), Barnes, B. J., PharmD (Co-Investigator), & Moriarty, P. M., MD (Co-Investigator). *Comparison of prescription fish oil and a fish oil supplement: A pilot study.* University of Kansas General Research Fund \$8,967, Submitted 2009 (June 2010 - May 2011).



Ruisinger, J. F. (Principal), Backes, J. M. (Co-Investigator), Gibson, C. A. (Co-Investigator), Sullivan, D. (Co-Investigator), Moriarty, P. M. (Co-Investigator), McConville, R., Smith, B. K. (Co-Investigator), & Kris-Etherton, P. M. (Co-Investigator). *Efficacy of Almonds Added to Chronic Statin Therapy*. University of Kansas General Research Fund/Almond Board of California \$45,000 (June 2007 - June 2009).

Backes, J. M. (Principal), Gibson, C. A. (Co-Investigator), Ruisinger, J. F. (Co-Investigator), & Moriarty, P. M. (Co-Investigator). *Safety and Efficacy of Policosanol added to Chronic Statin Therapy: a Pilot Study*. University of Kansas General Research Fund/Marcor \$69,000 (June 2006 - June 2008).

### **Internal Award**

#### Funded

Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. *High-dose Rosuvastatin Once Weekly Study (HD-ROWS)*. \$16,622 (December 2009 - November 2010).

### **KU Courses Taught**

#### Fall 2017

PHPR 513, Chemical Dependency Elective  
PHPR 662, Pharmacotherapy II

#### Spring 2017

PHPR 510, Medical Terminology Elective  
PHPR 661, Pharmacotherapy I  
PHPR 663, Pharmacotherapy III

#### Fall 2016

PHPR 647, Pharmacotherapy II  
PHPR 662, Pharmacotherapy II

#### Spring 2016

PHPR 510, Medical Terminology Elective  
PHPR 661, Pharmacotherapy I  
PHPR 670, Clinical Assessment

#### Fall 2015

PHPR 513, Chemical Dependency Elective  
PHPR 647, Pharmacotherapy II

#### Spring 2015

PHPR 502, Pharmacy Practice II Pharm Care  
PHPR 510, Medical Terminology Elective  
PHPR 670, Clinical Assessment

#### Fall 2014

PHPR 513, Chemical Dependency Elective  
PHPR 647, Pharmacotherapy II

Spring 2014  
PHPR 502, Pharmacy Practice II Pharm Care  
PHPR 510, Medical Terminology Elective

Fall 2013  
PHPR 513, Chemical Dependency Elective

Spring 2013  
PHPR 502, Pharmacy Practice II Pharm Care  
PHPR 510, Medical Terminology Elective

## Summary List of Courses Taught

### University of Kansas

#### *Didactic*

Chemical Dependency (PHPR 513) Co-coordinator. Fall 2010 to present. University of Kansas School of Pharmacy.  
Medical Terminology (PHPR 510) Co-developed this course and currently co-coordinate. Spring 2006 to present. University of Kansas School of Pharmacy.  
Pharmacotherapy II (PHPR 647) Fall 2006 to present. University of Kansas School of Pharmacy 4 lecture hours. Thrombosis  
Pharmacotherapy II (PHPR 647) Fall 2006 to 2016. University of Kansas School of Pharmacy 4 lecture hours. Stroke and TIA  
Pharmacotherapy I (PHPR 646) Spring 2005 to 2010. University of Kansas School of Pharmacy 2 lecture hours. GERD and PUD  
Pharmacy Practice III (PHPR 503) Fall 2000 to present. University of Kansas School of Pharmacy 8 lecture hours. Alternative Therapies  
Pharmacy Practice III (PHPR 503) Fall 2000 to 2014. University of Kansas School of Pharmacy 2 lecture hours. OTC and Rx Contraception  
Pharmacy Practice III (PHPR 503) Fall 2000 to 2014. University of Kansas School of Pharmacy 1 lecture hour. Vaginal and Menstrual Products  
Immunization Theory & Practice (PHAR 505). Spring 2007 to present. University of Kansas School of Pharmacy 1 lecture hour and 2 lab hours. HPV, RSV and  
Marketing/Documentation  
Pharmacotherapy I (PHPR 625) Spring 2003 to present. University of Kansas School of Pharmacy web-based Non-traditional Pharm.D. Program 2 lecture hours. Hormone Replacement Therapy and Osteoporosis  
Pharmacotherapy III (PHPR 627) Fall 2004 to present. University of Kansas School of Pharmacy web-based Non-traditional PharmD. Program 1 lecture hour. GERD/PUD  
Integrated Laboratory V (PHAR 530) Spring 2001 to 2007. University of Kansas School of Pharmacy 1 lecture hour, 2 lab hours. Immunizations  
Pharmacotherapy III (PHPR 648) Spring 2005. University of Kansas School of Pharmacy 2 lecture hours. GERD and PUD  
Pharmacy Practice I (PHPR 501) Fall 2004. University of Kansas School of Pharmacy 1 lecture hour. Ambulatory Care  
Pharmacy Practice II (PHPR 502) Spring 2001 to 2003. University of Kansas School of Pharmacy 1 lecture hour. Ambulatory Care Pharmacy Services



### *Experiential*

#### Residency Director and Preceptor

Community Pharmacy Practice Residency with Balls Food Stores – Accredited 2005  
Two residents each year for 53 weeks

#### Preceptor, Doctor of Pharmacy Students

KUMC Ambulatory Care Clinical Clerkship, July 2001 – present  
6-8 students per year

#### Preceptor, Community Pharmacy Residents

KUMC Ambulatory Care longitudinal rotation, July 2002-present  
One resident per year 2002-2011, two residents per year 2012 to present

#### Preceptor, Pharmacy Practice Management/Masters Residents

KUMC/KU Midwest Ambulatory Care Rotation, July 2002-2006  
One-two residents per year

## **University Service**

### University of Kansas

University of Kansas PGY1 Community-Based Pharmacy Residency Director - 2001 - Present

KU MedWest Antithrombotic Management Service Director - 2001 to 2009

KU Atherosclerosis and Lipid -Apheresis Center Pharmacist provider - 2000 - Present

## **School Service**

### University of Kansas

#### Faculty Executive Committee

Chair – August 2018- August 2019

Pharmacy Practice representative – August 2017-August 2018

#### Co-Advisor

American Pharmacists Association - Academy of Student Pharmacists. (2002 - 2010)

#### Coordinator

University of Kansas School of Pharmacy Teaching and Learning Curriculum for Pharmacists and Pharmacy Residents. Coordinate the Teaching and Learning Curriculum for Pharmacists and Pharmacy Residents (July 2016 - Present)

KU School of Pharmacy Residency Club - Organize 3 panel discussions and one residency showcase each academic year for students interested in pursuing a residency post graduation. (June 2016 - Present)

#### Member

Academic Misconduct Committee, KU School of Pharmacy. (2008 - 2011)

NTPD Program Admissions Committee, KU School of Pharmacy. (2005 - 2008)

ACPE sub-committee Facilities and Resources, KU School of Pharmacy. (2007)

IPPE Director Search Committee, KU School of Pharmacy. (2007)

## Department Service

### University of Kansas

#### Pharmacy Practice

##### Member

Tenure track search committee member. (October 2013 - May 2014)

## Professional Service

### National

##### Advisory Committee Member

American Pharmacists Association (APhA) Community Pharmacy Residency Program Advisory Panel. Appointed to two 3 year terms (March 2011 - March 2017)

##### Faculty

APhA Lipid Certificate Training Program. (2005 - 2010)

##### Judge

APhA Annual Meeting Posters. (2008)

##### Media Advisor

APhA OTC Media Advisor. (2004 - 2014)

##### Member

American Society of Health-System Pharmacists Commission on Credentialing – APhA liaison, Bethesda, MD, USA. (August 2013 - December 2016)

APhA Annual Meeting Abstract Review Committee. (2004)

##### New Practitioner Officer

APhA Academy of Pharmacy Practice and Management – Community and Ambulatory Practice Section. (2005)

##### Participant

American College of Cardiology 2016 LDL: Address the Risk Think Tank, Washington, DC. (September 19, 2016)

##### Reviewer

APhA Expert Review Panel for ACC/AHA Cholesterol and Risk Assessment Guidelines, Washington, DC, USA. Serve as expert reviewer for Cholesterol and Risk Assessment Guidelines (November 2013 and October 2018)

##### Reviewer, Journal Article

*Journal of the American Pharmacists Association.* (2008 - Present)

*The Annals of Pharmacotherapy.* (2006 - Present)

Surveyor

APhA Community Residency Accreditation Practitioner Surveyor (2006-present)

State

Professional Affairs Committee Member 2017 to present

Kansas Pharmacists Association

Annual Meeting Task Force Committee Member 2002-2003

Kansas Pharmacists Association